Medivir AB (“Medivir” or “the Company”) announces that the prospectus relating to Medivir’s rights issue (the “Rights Issue”) has been approved...
Read moreResolution regarding reduction of the share capital without cancellation of shares The extraordinary general meeting in Medivir Aktiebolag (publ) on 13...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a presentation entitled “Phase I study of the novel pro-drug...
Read moreStockholm — Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which...
Read more